Drug Approval | November 08, 2022
Zydus receives EIR with VAI from USFDA for Moraiya facility
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
The inspection concluded with no observation (FDA-483) issued.
The inspection of the facility was conducted from August 16-19, 2022.
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
With the receipt of the EIR, the inspection stands successfully closed.
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
For the first time in India – fast, precise and efficient calibration of multi-channel micropipettes
Subscribe To Our Newsletter & Stay Updated
